What We're Reading: Page 226
Industry reads hand-picked by our editors
Mar 12, 2019
Mar 11, 2019
-
The New York Times
An unvaccinated boy got tetanus. His Oregon hospital stay: 57 days and $800,000.
-
The Wall Street Journal
Bureau of prisons opens new investigation into Martin Shkreli
-
BioCentury
Top-down solution to the U.K. Orkambi debacle
-
Xconomy
The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski
Mar 08, 2019
-
Science
The war on 'prediabetes' could be a boon for pharma — but is it good medicine?
-
The Wall Street Journal
Trump Administration Weighs Publicizing Secret Rates Hospitals and Doctors Negotiate With Insurers
-
Evaluate
Off-the-shelf approaches keep cell therapy investors keen
-
Bloomberg
African pharma tycoon Saad falls from grace as Aspen plunges
Mar 07, 2019
-
The Wall Street Journal
Martin Shkreli Steers His Company From Prison—With Contraband Cellphone
-
Evaluate
The Gottlieb legacy: a surge in unproven treatments?
-
STAT
The mysterious dark money group behind a pharma-bashing ad campaign
-
JAMA Viewpoint
Prescription Drugs — List Price, Net Price, and the Rebate Caught in the Middle
Mar 06, 2019
-
Undark
For big pharma, a history of profiting from manufactured addiction
-
Genetic Engineering & Biotechnology News
Taking a new shot at tumor vaccines
-
The Wall Street Journal
A Doctor's Prescription for More AI in Medicine
-
Medical Marketing & Media
Meet pharma's digital chiefs
Mar 05, 2019
-
The New York Times
H.I.V. Is Reported Cured in a Second Patient, a Milestone in the Global AIDS Epidemic
-
Kaiser Health News
Big Pharma Gave Money To Patient Advocacy Groups Opposing Medicare Changes
-
Reuters
OxyContin maker Purdue Pharma exploring bankruptcy - sources
-
The Wall Street Journal
Celgene Odds Are in Investors' Favor
Mar 04, 2019
-
The New York Times
Drug Companies and Doctors Battle Over the Future of Fecal Transplants
-
Healthcare Dive
Mixing medicine and money: Why the rise of health system VCs is raising ethical concerns
-
The Economist
'Repurposing' off-patent drugs offers big hopes of new treatments
-
The Wall Street Journal
The Side Effects of Million-Dollar Drugs
Previous
